---
created: 2025-04-13
updated: 2025-04-13T10:51
id: K|Y-t2_HHr
specialty: obgyn
specialty_id: 45
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - source/ak-step1-v11::
  - theme/b&b::11-hematology::04-cancer-drugs::06-other-cancer-drugs
  - source/ak-step1-v11::
  - theme/b&b::20-repro::03-vagina,-cervix,-uterus::03-endometrial-disorders
  - source/ak-step1-v11::
  - theme/firstaid::05-pharmacology::03-toxicities-&-side-effects::03-drug-reactions---endocrine/reproductive
  - source/ak-step1-v11::
  - theme/firstaid::10-hematology-oncology::05-pharm::25-selective-estrogen-receptor-modulators::tamoxifen
  - source/ak-step1-v11::
  - theme/firstaid::15-repro::05-pharm::05-selective-estrogen-receptor-modulators
  - source/ak-step1-v11::
  - theme/firstaid::15-repro::05-pharm::05-selective-estrogen-receptor-modulators::tamoxifen
  - source/ak-step1-v11::
  - theme/nbme::29
  - source/ak-step1-v11::
  - source/ome-banner
  - source/ak-step1-v11::
  - theme/physeo::03-physiology::07-repro::06-integrated-female-physiology
  - source/ak-step1-v11::
  - theme/physeo::09-pharm::12-reproductive::03-raloxifene,-clomiphene,-tamoxifen
  - source/ak-step1-v11::
  - theme/pixorize::03-pharm::11-oncology::raloxifene-and-tamoxifen
  - source/ak-step1-v11::
  - theme/sketchypath::08-repro-&-gu::01-uterine-&-vulvovaginal-disorders::01-abnormal-uterine-bleeding-(aub)-&-endometriosis
  - source/ak-step1-v11::
  - theme/sketchypharm::reproductive
  - source/ak-step1-v11::
  - theme/uworld::100-999::500-599::581
  - source/ak-step1-v11::
  - theme/uworld::10000-99999::14000-14999::14920
  - source/ak-step1-v11::^other::^highyield::1-highyield
  - source/ak-step1-v11::^systems::reproductive::pharmacology
type: flashcard
---

# Question
Tamoxifen increases the risk of thromboembolic events and **endometrial** cancer

---

# Answer
Tamoxifen = selective estrogen receptor modulator = tx of ER+ breast CA = a prodrug metabolized by CYP2D to its active metabolite, endoxifen.  In the breast, estrogen receptor antagonist == competitive inhibition of estradiol binding to its receptor  Endometrial hyperplasia/CA = due to estrogen agonist activity in endometrial and bone tissue